Helicobacter pylori eradication: Metronidazole or tinidazole? Data from Turin, Italy

Minerva Gastroenterologica e Dietologica

Volumn 54, Issue 4, 2008, Pages 355-358

  Berrutti, M ^a   Pellicano, R ^a   Astegiano, M ^a   Smedile, A ^a   Saracco, G ^a   Morgando, A ^a   De Angelis, C ^a   Repici, A ^b   Fagoonee, S ^c   Leone, N ^d   Rizzetto, M ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d GRADENIGO HOSPITAL   (Italy)

Author keywords

Helicobacter pylori; Metronidazole; Tinidazole

Indexed keywords

AMOXICILLIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; TINIDAZOLE;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UREA BREATH TEST;

ANTI-INFECTIVE AGENTS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; ITALY; MALE; METRONIDAZOLE; MIDDLE AGED; TINIDAZOLE;

EID: 59749084745     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Pellicano R, Fagoonee S, Palestro G, Rizzetto M, Ponzetto A. Intestinal metaplasia, dysplasia, gastric cancer and Helicobacter pylori: epidemiological observations. Minerva Medica 2005;96:1-10.
2. Malfertheiner P, Mégraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
3. Zullo A, Perna F, Hassan C, Ricci C, Saracino I, Morini S. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther 2007;25:1429-34.
4. Fung HB, Doan TL. Tinidazole: a nitroimidazole antiprotozoal agent. Clin Ther 2005;27:1859-84.
5. Malfertheiner P, Mégraud F, O'Morain C, Hungins APS, Jones R, Axon A et al. Current concepts in the management of Helicobacter pylori infection-The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
6. Pellicano R, Smedile A, Ponzetto A, Berrutti M, Astegiano M, Saracco G et al. How accurate is the culture of Helicobacter pylori in a clinical setting? An appraisal. Panminerva Medica 2005;47:191-4.
7. Alarcon T, Domingo D, Lopez-Brea M. Antibiotic resistance problems with Helicobacter pylori. Int J Antimicrobial Agents 1999;12:19-26.
8. Mégraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84.
9. Thijs JC, Van Zwet AA, Thijs WJ, Van der Wouden EJ, Kooy A. One-week triple therapy with omeprazole, amoxycillin and tinidazole for Helicobacter pylori infection: the significance of imidazole resistance. Aliment Pharmacol Ther 1997;11:305-9.
10. Lahaie R, Farley A, Dallaire C. Bismuth-based quadruple therapy with bismuth subcitrate, metronidazole, tetracycline and omeprazole in the eradication of Helicobacter pylori. Can J Gastroenterol 2001;15:581-5.
11. Mégraud F, Occhialini A, Rossignol JF. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-reaction to metronidazole. Antimicrob Agents Chemoter 1998;42:2836-40.
12. Pellicano R, Palmas F, Ponzetto A, Astegiano M, Smedile A, Morgando A et al. Decreasing eradication rate of Helicobacter pylori infection with metronidazole-based triple therapy. A randomised study. Minerva Gastroenterol Dietol 2002;48:265-70.
13. Sito E, Konturek PC, Bielanski W, Kwiecine N, Konturek SJ, Baniukiewicz A et al. One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients. J Physiol Pharmacol 1996;47:221-8.
14. Goddard AF, Logan RP, Lawes S, Spiller RC. Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. Aliment Pharmacol Ther 1999;13:637-42.